Amylin Pharmaceuticals, Inc · San Diego, CA United States · (NASDAQ (GS): AMLN)
Company Description
More Companies in: San Diego, California
More Companies in These Related Industries: Pharmaceutical Preparation Mfg
View Amylin Pharmaceuticals, Inc Locations On A US Map
This link will open in a new window
This link will open in a new window Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Development partner Eli Lilly markets Byetta worldwide and is responsible for the development of Byetta in international markets. Amylin's US-based sales force co-promotes Byetta with Eli Lilly and markets Symlin on its own. The company is working on other diabetes drugs, including a once-weekly version of Byetta, as well as treatments for obesity. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Amylin Pharmaceuticals, Inc Reports
No subscription, no problem.
Download presentation-ready reports for this company now.
Download presentation-ready reports for this company now.
From company profiles to the competitive landscape, Hoover’s offers immediate access to individual reports.
Key Amylin Pharmaceuticals, Inc Financials
| Company Type | Public - NASDAQ (GS): AMLN Headquarters |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | $840.1 |
| 2008 Employees | 1,800 |
Amylin Pharmaceuticals, Inc Executives
36 executives listed for Amylin Pharmaceuticals, Inc's San Diego, CA location.
| Title | Name & Bio | Contact |
| Chairman | Paulo Costa | |
| President, CEO, and Director | Daniel Bradbury | |
| SVP Finance and CFO | Mark Foletta |
Competition
Competitive Landscape for Amylin Pharmaceuticals, Inc
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Amylin Pharmaceuticals, Inc Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!